NasdaqGS:BIIBBiotechs
Assessing Biogen (BIIB) Valuation After Recent Share Price Momentum And Pipeline Prospects
Why Biogen (BIIB) is on investors’ radar today
Biogen (BIIB) has drawn fresh attention after recent share price moves, with the stock up about 9% over the past month but showing a roughly 5% decline over the past 3 months.
See our latest analysis for Biogen.
The recent 8.98% 1 month share price return, alongside a 7.63% year to date share price return and 61.65% 1 year total shareholder return, suggests momentum has picked up again after weaker 3 year and 5 year total shareholder returns.
If...